Extreme Urinary Betaine Losses in Type 2 Diabetes Combined with Bezafibrate Treatment are Associated with Losses of Dimethylglycine and Choline but not with Increased Losses of Other Osmolytes

Residual macrovascular risk in 2013: what have we learned?

(2014) Jean-Charles Fruchart et al.   Cardiovascular Diabetology

Prognostic value of choline and betaine depends on intestinal microbiota-generated metabolite trimethylamine-N-oxide

(2014) Z. Wang et al.   EUROPEAN HEART JOURNAL

Fenofibrate causes elevation of betaine excretion but not excretion of other osmolytes by healthy adults

(2014) Michael Lever et al.   Journal of Clinical Lipidology

Osmotic regulation of hepatic betaine metabolism

(2013) Lars Hoffmann et al.   AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY

Plasma Dimethylglycine and Risk of Incident Acute Myocardial Infarction in Patients With Stable Angina Pectoris

(2013) Gard Frodahl Tveitevåg Svingen et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

Dietary Choline and Betaine Intakes Vary in an Adult Multiethnic Population

(2013) Kim M. Yonemori et al.   JOURNAL OF NUTRITION

Intestinal microbiota metabolism of l-carnitine, a nutrient in red meat, promotes atherosclerosis

(2013) Robert A Koeth et al.   NATURE MEDICINE

Intestinal Microbial Metabolism of Phosphatidylcholine and Cardiovascular Risk

(2013) W.H. Wilson Tang et al.   NEW ENGLAND JOURNAL OF MEDICINE

Assessment of Urinary Betaine as a Marker of Diabetes Mellitus in Cardiovascular Patients

(2013) Hall Schartum-Hansen et al.   PLoS One

The Diabetes Excess Weight Loss (DEWL) Trial: a randomised controlled trial of high-protein versus high-carbohydrate diets over 2 years in type 2 diabetes

(2012) J. D. Krebs et al.   DIABETOLOGIA

Evaluation and Treatment of Hypertriglyceridemia: An Endocrine Society Clinical Practice Guideline

(2012) Lars Berglund et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

The Contrasting Relationships between Betaine and Homocysteine in Two Clinical Cohorts are Associated with Plasma Lipids and Drug Treatments

(2012) Michael Lever et al.   PLoS One

Betaine and Secondary Events in an Acute Coronary Syndrome Cohort

(2012) Michael Lever et al.   PLoS One

Betaine excretion correlates with plasma homocysteine when plasma lipids are elevated

(2011) Michael Lever et al.   CLINICAL BIOCHEMISTRY

Use of Fibrates in the United States and Canada

(2011) Cynthia A. Jackevicius   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease

(2011) Zeneng Wang et al.   NATURE

Plasma Lipids and Betaine Are Related in an Acute Coronary Syndrome Cohort

(2011) Michael Lever et al.   PLoS One

The clinical significance of betaine, an osmolyte with a key role in methyl group metabolism

(2010) Michael Lever et al.   CLINICAL BIOCHEMISTRY

Fibrates: no ACCORD on their use in the treatment of dyslipidaemia

(2010) Anthony S Wierzbicki   CURRENT OPINION IN LIPIDOLOGY

Fibrates may Cause an Abnormal Urinary Betaine Loss Which is Associated with Elevations in Plasma Homocysteine

(2009) Michael Lever et al.   CARDIOVASCULAR DRUGS AND THERAPY

Antidiabetic Action of Bezafibrate in a Large Observational Database

(2009) J. H. Flory et al.   DIABETES CARE

Combined therapy in the treatment of dyslipidemia

(2009) Željko Reiner   FUNDAMENTAL & CLINICAL PHARMACOLOGY

The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in dyslipidaemic patients

(2008) Jean-Charles Fruchart et al.   Diabetes & Vascular Disease Research

Is There a Role for Fibrates in the Management of Dyslipidemia in the Metabolic Syndrome?

(2007) Philip J. Barter et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY